Anoro Ellipta

Anoro Ellipta is a fixed-dose combination inhaler containing umeclidinium, a long-acting muscarinic antagonist (LAMA), and vilanterol, a long-acting beta-2 adrenoceptor agonist (LABA).

It is indicated for the maintenance bronchodilator treatment of airflow obstruction in adults with chronic obstructive pulmonary disease (COPD).

Umeclidinium blocks muscarinic M3 receptors in the airway smooth muscle, preventing acetylcholine-mediated bronchoconstriction.

Vilanterol stimulates beta-2 receptors, causing smooth muscle relaxation and bronchodilation.

The combination of two bronchodilators with complementary mechanisms provides greater and more sustained improvement in lung function compared to either component alone.

Anoro Ellipta is delivered via the Ellipta dry powder inhaler, a simple, breath-actuated device that requires only one inhalation per dose.

The device includes a dose counter and is designed for ease of use.

Clinical trials have demonstrated that Anoro significantly improves FEV1, reduces rescue inhaler use, and improves symptoms compared with monotherapy in COPD patients.

Inhale one dose from the Ellipta device once daily at the same time each day.

Open the cover of the inhaler fully until you hear a click, breathe out gently away from the mouthpiece, then inhale steadily and deeply through the device.

Hold your breath for 3 to 4 seconds before breathing out slowly. Close the cover after use. Anoro is a maintenance treatment; it is not for relieving sudden breathlessness.

Always keep a short-acting reliever inhaler available.

One inhalation (umeclidinium 55 micrograms and vilanterol 22 micrograms) once daily. Do not exceed one inhalation per day.

No dose adjustment is required in elderly patients or those with renal impairment. Use with caution in patients with severe hepatic impairment.

Anoro is not indicated for patients under 18 years of age.

Common (1 in 10 to 1 in 100): upper respiratory tract infection, nasopharyngitis, headache, cough, urinary tract infection, pharyngitis, sinusitis.

Uncommon (1 in 100 to 1 in 1,000): constipation, dry mouth, tachycardia, supraventricular tachycardia, atrial fibrillation, palpitations, rash, dysgeusia.

Rare (1 in 1,000 to 1 in 10,000): paradoxical bronchospasm, urinary retention, blurred vision, angle-closure glaucoma.

If you experience difficulty passing urine or sudden eye pain, seek medical attention immediately.

Anoro should not be used to treat acute episodes of bronchospasm. Deterioration of COPD control or increasing rescue inhaler use warrants medical reassessment.

The anticholinergic component (umeclidinium) should be used with caution in patients with narrow-angle glaucoma, urinary retention, or prostatic hyperplasia.

The LABA component (vilanterol) should be used cautiously in patients with cardiovascular disorders, convulsive disorders, thyrotoxicosis, and diabetes.

Hypokalaemia may occur with high-dose beta-2 agonists. Anoro is not indicated for asthma.

Anoro is contraindicated in patients with known hypersensitivity to umeclidinium, vilanterol, or any of the excipients, including lactose monohydrate (which contains milk proteins).

It should not be used for the treatment of asthma, as its safety and efficacy in asthma have not been established.